The MERLIN-TIMI 36 ( Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36 ) trial randomized non-ST-elevation ACS patients to ranolazine or placebo , with no exclusion for renal dysfunction ( except dialysis ) .